Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nitazenes represent a growing threat to public health in Europe
Isabelle Giraudon, Katri Abel‐Ollo, Diāna Vanaga-Arāja, et al.
The Lancet Public Health (2024) Vol. 9, Iss. 4, pp. e216-e216
Open Access | Times Cited: 11

Showing 11 citing articles:

The public health risks of counterfeit pills
Joseph Friedman, Daniel Ciccarone
The Lancet Public Health (2025) Vol. 10, Iss. 1, pp. e58-e62
Open Access | Times Cited: 1
In vitro structure–activity relationships and forensic case series of emerging 2-benzylbenzimidazole ‘nitazene’ opioids
Liam M. De Vrieze, Sara E. Walton, Eline Pottie, et al.
Archives of Toxicology (2024) Vol. 98, Iss. 9, pp. 2999-3018
Open Access | Times Cited: 7
Utilization of drug checking services in Austria: a cross-sectional online survey
Alexandra Karden, Tobias Schiffler, Cornelia Feichtinger, et al.
Harm Reduction Journal (2025) Vol. 22, Iss. 1
Open Access
The UHPLC-MS/MS method for the determination of 26 synthetic benzimidazole opioids (nitazene analogs) with isomers separation
Olga Wachełko, Kaja Tusiewicz, Paweł Szpot, et al.
Journal of Pharmaceutical and Biomedical Analysis (2025) Vol. 260, pp. 116796-116796
Closed Access
Early identification of the use of potent benzylbenzimidazoles (nitazenes) through wastewater analysis: Two years of data from 22 countries
Richard Bade, Dhayaalini Nadarajan, Wayne Hall, et al.
Addiction (2025)
Open Access
Commentary on Copeland et al.: Does xylazine in the United Kingdom foreshadow a European synthetic polysubstance drug crisis?
Joseph Friedman
Addiction (2024) Vol. 119, Iss. 7, pp. 1310-1312
Open Access | Times Cited: 4
Europe must continue to lead on harm reduction
B. Kahn, Michel D. Kazatchkine
Harm Reduction Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 1
Protective or potentially harmful? Altering drug consumption behaviors in response to xylazine adulteration
William H. Eger, Marina Plesons, Tyler S. Bartholomew, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Potency, dissociation kinetics and reversibility of fentanyls and nitazenes by naloxone at the μ opioid receptor
Norah Alhosan, Damiana Cavallo, Marina Santiago, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Syringe services program staff and participant perspectives on changing drug consumption behaviors in response to xylazine adulteration
William H. Eger, Marina Plesons, Tyler S. Bartholomew, et al.
Harm Reduction Journal (2024) Vol. 21, Iss. 1
Open Access
Slow dissociation kinetics of fentanyls and nitazenes correlates with reduced sensitivity to naloxone reversal at the μ‐opioid receptor
Norah Alhosan, Damiana Cavallo, Marina Santiago, et al.
British Journal of Pharmacology (2024)
Open Access
Characterization of novel nitazene recreational drugs: Insights into their risk potential from in vitro µ-opioid receptor assays and in vivo behavioral studies in mice
Marthe M. Vandeputte, Grant C. Glatfelter, Donna Walther, et al.
Pharmacological Research (2024) Vol. 210, pp. 107503-107503
Open Access
Page 1

Scroll to top